These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 12031916)
1. Prognostic significance of lymphocyte morphology in patients with advanced chronic lymphocytic leukemia treated with first line therapy of fludarabine + prednisone. Mauro FR; Gentile M; Mancini F; Giannarelli D; Guarini A; De Propriis MS; Cerretti R; Foa R Haematologica; 2002 Jun; 87(6):602-8. PubMed ID: 12031916 [TBL] [Abstract][Full Text] [Related]
2. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study. Mauro FR; Zinzani P; Zaja F; Gentile M; Vegna ML; Stefoni V; Marin L; Fanin R; Baccarani M; Tura S; Mandelli F Haematologica; 2003 Dec; 88(12):1348-57. PubMed ID: 14687987 [TBL] [Abstract][Full Text] [Related]
3. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases]. Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412 [TBL] [Abstract][Full Text] [Related]
4. Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy. Liso V; Molica S; Capalbo S; Pogliani E; Battista C; Broccia G; Montillo M; Cuneo A; Leoni P; Specchia G; Castoldi G Haematologica; 2001 Nov; 86(11):1165-71. PubMed ID: 11694402 [TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group. Eichhorst BF; Busch R; Obwandner T; Kuhn-Hallek I; Herschbach P; Hallek M; J Clin Oncol; 2007 May; 25(13):1722-31. PubMed ID: 17389338 [TBL] [Abstract][Full Text] [Related]
6. Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. The French Cooperative Group on Chronic Lymphocytic Leukemia. Semin Oncol; 1993 Oct; 20(5 Suppl 7):21-3. PubMed ID: 8235691 [TBL] [Abstract][Full Text] [Related]
8. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients. Mauro FR; Foa R; Meloni G; Gentile M; Giammartini E; Giannarelli D; De Propris MS; Rapanotti MC; de Fabritiis P; Mandelli F Haematologica; 2002 Sep; 87(9):926-33. PubMed ID: 12217804 [TBL] [Abstract][Full Text] [Related]
9. [Prognostic significance of immunoglobulin variable region gene mutations in B-CLL patients treated with combination therapy fludarabine plus cyclophosphamide]. Nikitin EA; Stadnik EA; Lorie IuIu; Biderman BV; Tsyba NN; Salogub GN; Kolosheĭnova TI; Kolosova LIu; Risinskaia NA; Zaritskiĭ IuA; Kovaleva LG; Sudarikov AB Ter Arkh; 2007; 79(7):66-70. PubMed ID: 17802794 [TBL] [Abstract][Full Text] [Related]
10. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266 [TBL] [Abstract][Full Text] [Related]
11. Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy. Eichhorst BF; Busch R; Schweighofer C; Wendtner CM; Emmerich B; Hallek M; Br J Haematol; 2007 Jan; 136(1):63-72. PubMed ID: 17083342 [TBL] [Abstract][Full Text] [Related]
12. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Tsimberidou AM; Keating MJ; Giles FJ; Wierda WG; Ferrajoli A; Lerner S; Beran M; Andreeff M; Kantarjian HM; O'Brien S Cancer; 2004 Jun; 100(12):2583-91. PubMed ID: 15197800 [TBL] [Abstract][Full Text] [Related]
13. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317 [TBL] [Abstract][Full Text] [Related]
14. Fludarabine combined with cyclophosphamid is highly effective in the treatment of chronic lymphocytic leukemia. Tóthová E; Kafková A; Fricová M; Guman T; Stecová N Neoplasma; 2003; 50(6):433-7. PubMed ID: 14689065 [TBL] [Abstract][Full Text] [Related]
15. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364 [TBL] [Abstract][Full Text] [Related]
16. Fludarabine and prednisone in pretreated and refractory B-chronic lymphocytic leukemia (B-CLL) in advanced stages. De Rossi G; Mauro FR; Caruso R; Monarca B; Mandelli F Haematologica; 1993; 78(3):167-71. PubMed ID: 8375746 [TBL] [Abstract][Full Text] [Related]
17. Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration. Laurenti L; Tarnani M; De Padua L; Efremov DG; Zini G; Garzia M; Piccirillo N; Chiusolo P; Sorà F; Innocenti I; Sica S; Leone G Ann Hematol; 2008 Nov; 87(11):891-8. PubMed ID: 18587576 [TBL] [Abstract][Full Text] [Related]
18. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974 [TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of the FAB morphological criteria in chronic lymphocytic leukemia: correlations with IgVH gene mutational status and other prognostic markers. Schwarz J; Mikulenková D; Cermáková M; Polanská V; Michalová K; Marinov I; Campr V; Ransdorfová S; Marková J; Pavlistová L; Brezinová J; Sajdová J; Sponerová D; Volková Z; Benesová K; Cermák J; Vítek A; Cetkovský P Neoplasma; 2006; 53(3):219-25. PubMed ID: 16652191 [TBL] [Abstract][Full Text] [Related]
20. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma. Zinzani PL; Levrero MG; Lauria F; Rondelli D; Zaja F; Russo D; Fanin R; De Rossi G; Mauro FR; Bendandi M; Gozzetti A; Dianzani F; Mandelli F; Tura S Haematologica; 1994; 79(1):55-60. PubMed ID: 15378949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]